Trials / Completed
CompletedNCT00747123
A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma
A Phase 2a, Multi-Center, Randomized, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ACE-011 (hActRIIA-IgG1) in Patients With Osteolytic Lesions of Multiple Myeloma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Multi-center, randomized, multiple-dose study to evaluate the safety, tolerability and efficacy of ACE-011 in patients with osteolytic lesions of multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ACE-011 | ACE-011 given by the subcutaneous route of administration monthly for 4 doses. |
| BIOLOGICAL | Placebo | Placebo given by the subcutaneous route of administration monthly for 4 doses. |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2008-09-04
- Last updated
- 2024-10-03
- Results posted
- 2024-10-03
Locations
2 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT00747123. Inclusion in this directory is not an endorsement.